Home » Stocks » Adaptive Biotechnologies

Adaptive Biotechnologies Corporation (ADPT)

Stock Price: $49.50 USD 2.57 (5.48%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 6.72B
Revenue (ttm) 92.17M
Net Income (ttm) -99.50M
Shares Out 135.79M
EPS (ttm) -0.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $49.50
Previous Close $46.93
Change ($) 2.57
Change (%) 5.48%
Day's Open 47.35
Day's Range 47.27 - 49.68
Day's Volume 655,392
52-Week Range 15.19 - 54.20

More Stats

Market Cap 6.72B
Enterprise Value 6.20B
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 135.79M
Float 130.33M
EPS (basic) -0.66
EPS (diluted) -0.79
FCF / Share -1.03
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.22M
Short Ratio 4.60
Short % of Float 4.00%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 72.93
PB Ratio 12.03
Revenue 92.17M
Operating Income -113.77M
Net Income -99.50M
Free Cash Flow -130.68M
Net Cash 526.79M
Net Cash / Share 3.88
Gross Margin -8.58%
Operating Margin -123.44%
Profit Margin -108.00%
FCF Margin -141.79%
ROA -9.77%
ROE -24.57%
ROIC -19.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 7
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(10.10% upside)
Current: $49.50
Target: 54.50
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth52.83%44.77%-
Gross Profit62.8036.0022.77
Operating Income-78.39-49.76-44.48
Net Income-68.61-46.45-42.83
Shares Outstanding69.1712.6312.20
Earnings Per Share-1.01-3.67-3.50
Operating Cash Flow205-32.26-34.86
Capital Expenditures-11.20-6.30-2.21
Free Cash Flow194-38.56-37.07
Cash & Equivalents579165192
Total Debt36.61--
Net Cash / Debt542165192
Book Value571-258-225
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Adaptive Biotechnologies Corporation
Country United States
Employees 453
CEO Chad Robins

Stock Information

Ticker Symbol ADPT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ADPT
IPO Date June 27, 2019


Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.